Trials & Filings

Kodiak Sciences Receives Positive Phase I Data

Phase 1b study complete for KSI-301, treatment of (wet) AMD, DME, and RVO

Kodiak Sciences Inc. achieved positive interim results from the ongoing Phase 1b study of KSI-301, its investigational intravitreal anti-VEGF antibody biopolymer conjugate in patients with anti-VEGF treatment-naïve neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema due to retinal vein occlusion (RVO).     Across all three diseases under study, strong improvements in vision and retinal anatomy were observed over 12 weeks. In the study, pati...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters